Answers are grounded in this paper and cite their sources.
To the Editor: In their letter to the editor, Salmasi et al. (Aug. 8 issue) 1 describe a patient with monoclonal gammopathy of undetermined significance and low-level monoclonal protein with anti–platelet factor 4 (PF4) antibody properties, a rare occurrence that had been previously documented in only three other cases. Severe, recurrent thrombotic events that occur despite anticoagulation therapy show that antithrombotic therapy alone is inadequate to control hypercoagulability. However, anti–PF4 antibody activity is only one manifestation of the broader prothrombotic properties of monoclonal immunoglobulins, which can also have highly thrombogenic effects by reducing the levels of natural anticoagulants or having antiphospholipid . . .
No takes yet. Share an insight, caveat, or question.
A 2024 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: